Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.